Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 30;184(20):5077-5081.
doi: 10.1016/j.cell.2021.09.010. Epub 2021 Sep 17.

COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants

Muge Cevik  1 , Nathan D Grubaugh  2 , Akiko Iwasaki  3 , Peter Openshaw  4
Affiliations

COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants

Muge Cevik et al. Cell. .

Abstract

As the SARS-CoV-2 pandemic evolves, new variants continue to emerge. Some highly transmissible variants, such as Delta, also raised concerns about the effectiveness provided by current vaccines. Understanding immunological correlates of protection and how laboratory findings correspond to clinical effectiveness is imperative to shape future vaccination strategies.

PubMed Disclaimer

Conflict of interest statement

Declarations of interest M.C. has nothing to declare. N.D.G. is a paid consultant for Tempus Labs. P.O. declares joint grant funding from the Medical Research Council UK and GlaxoSmithKline. A.I. is a co-founder of RIGImmune and serves on its scientific advisory board and consulted for Adaptive Biotechnologies, Boehringer Ingelheim, Vedanta, and Spring Discovery. She is on the scientific advisory board of 4BIO Capital. She holds a patent entitled “Interferon Production Using Short RNA Duplexes.” Issued. United States Patent Number 10947543.

References

    1. Abu-Raddad L.J., Chemaitelly H., Butt A.A. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. N. Engl. J. Med. 2021;385:187–189. - PMC - PubMed
    1. Braun K., Moreno G., Wagner C., Accola M.A., Rehrauer W.M., Baker D., Koelle K., O’Connor D.H., Bedford T., Friedrich T.C., et al. Limited within-host diversity and tight transmission bottlenecks limit SARS-CoV-2 evolution in acutely infected individuals. bioRxiv. 2021 2021.04.30.440988. - PMC - PubMed
    1. Corbett K.S., Werner A., O’Connell S., Gagne M., Lai L., Moliva J., Flynn B., Choi A., Koch M., Foulds K.E., et al. Evaluation of mRNA-1273 against SARS-CoV-2 B.1.351 Infection in Nonhuman Primates. bioRxiv. 2021 2021.05.21.445189. - PubMed
    1. Dejnirattisai W., Zhou D., Supasa P., Liu C., Mentzer A.J., Ginn H.M., Zhao Y., Duyvesteyn H.M.E., Tuekprakhon A., Nutalai R., et al. Antibody evasion by the P.1 strain of SARS-CoV-2. Cell. 2021;184:2939–2954.e9. - PMC - PubMed
    1. Geers D., Shamier M.C., Bogers S., den Hartog G., Gommers L., Nieuwkoop N.N., Schmitz K.S., Rijsbergen L.C., van Osch J.A.T., Dijkhuizen E., et al. SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees. Sci. Immunol. 2021;6:eabj1750. - PMC - PubMed